Professor of Medicine
Medical College of Georgia at Augusta University
Augusta, GA, United States
Jose A. Vazquez, MD, FACP, FIDSA; Professor of Medicine, Chief, Division of Infectious Diseases
Chair, Antimicrobial Stewardship Program, Chair, Institutional Review Board – A (Biomedical); Director, Infectious Disease Translational Research Unit (TRU-ID) at Medical College of Georgia/Augusta University, Augusta, Georgia.
He is a member of several professional societies, including the American College of Physicians, American Society for Microbiology, HIV Medicine Association, Infectious Disease Society of America, International Society for Human and Animal Mycology, Medical Mycology Society of the Americas, and the National Foundation for Infectious Diseases, among others. In addition, he is also on the Board of Directors of the Mycosis Study Group. Dr. Vazquez has published over 500 manuscripts, abstracts, case reports, and book chapters on various Infectious Disease topics, especially in the area of fungal infections and polymicrobial biofilms. His research includes the epidemiology and management of mucosal candidiasis, invasive candidiasis, as well as the management of systemic fungal infections. His current research interest includes the characterization of polymicrobial biofilms, especially Candida/Staphylococcus and Aspergillus/Pseudomonas. He is the Principal Investigator in over 10 clinical trials which include trteatment for COVID, the treatment of multidrug resistant gram negative infections producing complicated urinary tract infections, the treatment of multi-drug resistant candida infections, including C. auris, using novel oral and parenteral antifungal compounds, and long-acting antifungals. His basic research interest includes the evaluation of novel methods used to treat infections due to MDROs. This includes novel agents, specifically biofilm disrupting agents (BDAs). He is also involved with studies evaluating the management of chronic wounds, the management of multi-drug resistant bacterial and fungal infections, antifungal susceptibility, antifungal resistance mechanisms and the rapid diagnosis of fungal infections.
Disclosure(s): Astellas Pharma Inc.: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); Cidara: Advisor/Consultant (Ongoing), Grant/Research Support (Ongoing); F2G: Advisor/Consultant (Ongoing); Scynexis: Grant/Research Support (Ongoing)
164 - Clinical Management of Fungal Infections
Friday, October 13, 2023
1:45 PM – 3:00 PM US ET
1902 - Candidiasis: Where Are We Now?
Friday, October 13, 2023
1:45 PM – 2:10 PM US ET